Stocks and Investing
Stocks and Investing
Tue, March 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Danielle Brill Downgraded (ACAD) to Buy and Decreased Target to $35 on, Mar 9th, 2021
Danielle Brill of Raymond James, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Buy and Decreased Target from $65 to $35 on, Mar 9th, 2021.
Danielle has made no other calls on ACAD in the last 4 months.
There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Danielle's Rating of Hold.
This is the rating of the analyst that currently disagrees with Danielle
- Vamil Divan of "Mizuho" Initiated at Strong Buy and Held Target at $69 on, Wednesday, December 16th, 2020
Contributing Sources